Company profile
TRISALUS LIFE SCIENCES, INC.
NASDAQ:TLSIMedical Specialities
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IPILIMUMAB | phase1_2 | — | 128 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04935229 | phase1 | terminated | 2021-08-02 | 2024-07-17 | TriSalus Life Sciences, Inc. | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma |
| NCT05220722 | phase1_2 | terminated | 2022-03-02 | 2024-07-31 | TriSalus Life Sciences, Inc. | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors |
| NCT05607953 | phase1 | active_not_recruiting | 2023-03-01 | 2027-09-01 | TriSalus Life Sciences, Inc. | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma |
FDA applications (0)
No records yet.